Golden Lee Scott 4

What Happened Golden Lee Scott, EVP and Chief Medical Officer of PTC Therapeutics (PTCT), sold 10,000 common shares on March 5, 2026 at $63.38 per share, for proceeds of $633,800. The transaction is reported as a sale (code S) and was effected pursuant to a written Rule 10b5-1 trading plan adopted December 4, 2025. Sales are typically routine cashing-out transactions and do not necessarily indicate a change in insider sentiment.

Key Details

• Transaction date and price: March 5, 2026 — 10,000 shares sold at $63.38 each (total $633,800).
• Method: Report lists "open market or private sale" (sale reported under code S); filing notes it was executed under a 10b5-1 plan.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Transaction effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 4, 2025.
• Filing date: Form 4 was filed March 9, 2026 (four days after the trade); Form 4s are generally due within two business days, so this filing appears later than the usual reporting window.

Context Sales executed under pre-established 10b5-1 plans are common ways for insiders to diversify or meet liquidity needs while avoiding timing issues; such plans can limit what the sale implies about insider views. For retail investors, note this is a sale (liquidation), not a purchase or option exercise — purchases typically carry more weight as potential bullish signals.